Los Angeles, CA, August 18, 2006 – A study published this month in Microbes and Infection demonstrated that the probiotic strains Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ were efficacious in treating bacterial vaginosis (BV) and increasing the population of beneficial lactobacillus organisms within the vagina. Jarrow Formula’s Fem-Dophilus is a branded vaginal probiotic product consisting of the exact strains, Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™, used in the study. Fem-Dophilus is the only oral probiotic backed by clinical studies for restoring and maintaining a healthy vaginal flora and reducing the risk of urogenital infections.
The study enrolled 125 premenopausal women diagnosed with BV. The subjects were treated with oral metronidazole (500 mg) twice daily from days 1 to 7, and randomized to receive L. rhamnosus GR-1™ and L. reuteri RC-14™ or a placebo from days 1 to 30. At the end of the study, 88% of the women in the group treated with an antibiotic plus GR-1 and RC-14 were cured while only 44% of the women treated with antibiotics and no probiotics recovered from the BV. A total of 106 subjects returned for a 30-day follow-up of which 88% were cured in the antibiotic/probiotic group compared to 40% in the antibiotic/placebo group. Of the remaining subjects, 30% in the placebo group and none in the probiotic group had BV.
Jarrow Formula’s Fem-Dophilus features the world's most documented probiotic strains for women's health, Lactobacillus rhamnosus GR-1™ and Lactobacillus reuteri RC-14™ , discovered and developed by Drs. Gregor Reid and Andrew Bruce of Urex Biotech, Inc., and is produced and marketed globally by Chr. Hansen, a world leader in probiotics.
Research has confirmed that GR-1™ and RC-14™, taken as an oral supplement, colonizes and protects the vaginal tract. More than 20 years of research has shown that GR-1™ and RC-14™ helps to restore and maintain the balance of flora important to vaginal health and the health of the urinary tract overall.
“This study is very impressive considering that the standard treatment with metronidazole antibiotic drug only cured 44% of the patients while the addition of GR-1™ and RC-14™ increased the cure rate to 88%,” said Peilin Guo, MS, RD and vice president of Functional Foods at Jarrow Formulas. “In addition, antibiotics are known to cause vicious cycles of recurrent infection because of their wide spectrum killing of both pathogenic and probiotic bacteria. Fem-Dophilus offers an effective and natural remedy for improving vaginal and urinary tract health as well as the quality of life of women.”
Patented Fem-Dophilus is manufactured at a Good Manufacturing Practices (GMP) pharmaceutical facility under strict quality control to ensure potency and consistency. The probiotic strains in Fem-Dophilus are in a proprietary polysaccharide matrix, which protects the bacteria from stomach acid and enhances probiotic bacteria survival to the lower intestine.
Jarrow Formulas is a nutritional supplement formulator and marketer founded in 1977 and incorporated in 1988. The company markets its products throughout the United States and internationally in more than 20 countries in Europe, Asia, Israel and Latin America. The company offers a complete line of nutritional products that includes vitamins, minerals, probiotics, standardized herbal concentrates, amino acids, enzymes and enteral nutrition formulations. Jarrow Formulas, Inc. is active in regulatory affairs, helping to maintain American’s rights to free access to dietary supplements. Its products are manufactured by Jarrow Industries Incorporated, a pharmaceutical quality facility located in Santa Fe Springs, CA. For more information, contact Mark Becker, Director, Advertising/Communications toll free at (800) 726-0886 or access the Jarrow Formulas Web site at www.Jarrow.com.